About Mereo BioPharma
Mereo BioPharma is a company based in London (United Kingdom) founded in 2015 by John Richard, Charles Sermon, and Denise Scots Knight.. Mereo BioPharma has raised $119 million across 6 funding rounds from investors including Astrazeneca, Citadel and Orbimed. The company has 56 employees as of December 31, 2021. Mereo BioPharma has completed 1 acquisition, including Mereo BioPharma. Mereo BioPharma offers products and services including Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and Leflutrozole. Mereo BioPharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter London, United Kingdom
- Employees 56 as on 31 Dec, 2021
- Founders John Richard, Charles Sermon, Denise Scots Knight
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mereo Biopharma 1 Limited
- Date of Incorporation 18 Jun, 2015
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$119 M (USD)
in 6 rounds
-
Latest Funding Round
$70 M (USD), Post-IPO
Jun 04, 2020
-
Investors
Astrazeneca
& 11 more
-
Employee Count
56
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mereo BioPharma
Mereo BioPharma is a publicly listed company on the NASDAQ with ticker symbol MREO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mereo BioPharma
Mereo BioPharma offers a comprehensive portfolio of products and services, including Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and Leflutrozole. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for Osteogenesis Imperfecta in clinical development.
Treatment for alpha-1 antitrypsin deficiency lung disease.
Potential treatment in biopharmaceutical pipeline.
Development for rare disease applications.
Part of rare disease therapy pipeline.
Explored for rare disease treatment options.
Unlock access to complete
Unlock access to complete
Funding Insights of Mereo BioPharma
Mereo BioPharma has successfully raised a total of $119M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $70 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $70.0M
-
First Round
First Round
(29 Jun 2015)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Post-IPO - Mereo BioPharma | Valuation |
investors |
|
| Feb, 2020 | Amount | Post-IPO - Mereo BioPharma | Valuation |
investors |
|
| Feb, 2020 | Amount | Post-IPO - Mereo BioPharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mereo BioPharma
Mereo BioPharma has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Astrazeneca, Citadel and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mereo BioPharma
Mereo BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Mereo BioPharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Monoclonal antibodies targeting cancer stem cell pathways are developed.
|
2004 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Mereo BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mereo Biopharma Comparisons
Competitors of Mereo BioPharma
Mereo BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mereo Biopharma
Frequently Asked Questions about Mereo BioPharma
When was Mereo BioPharma founded?
Mereo BioPharma was founded in 2015.
Where is Mereo BioPharma located?
Mereo BioPharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Mereo BioPharma?
Denise Scots Knight is the current CEO of Mereo BioPharma. They have also founded this company.
Is Mereo BioPharma a funded company?
Mereo BioPharma is a funded company, having raised a total of $119M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $28M, raised on Jun 29, 2015.
How many employees does Mereo BioPharma have?
As of Dec 31, 2021, the latest employee count at Mereo BioPharma is 56.
What does Mereo BioPharma do?
Developer of therapeutics for cancer and rare diseases. The companys pipeline includes Etigilimab for metastatic solid tumors, Alvelestat for the treatment of severe Alpha-1 Antitrypsin Deficiency and COVID-19, Setrusumab for the treatment of Osteogenesis Imperfecta, Navicixizumab for the treatment of platinum-resistant ovarian cancer, Acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease, and Leflutrozole for the treatment of male infertility associated with hypogonadotropic hypogonadism.
Who are the top competitors of Mereo BioPharma?
Mereo BioPharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Mereo BioPharma offer?
Mereo BioPharma offers Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and 2 more products and services.
Is Mereo BioPharma publicly traded?
Yes, Mereo BioPharma is publicly traded on NASDAQ under the ticker symbol MREO.
How many acquisitions has Mereo BioPharma made?
Mereo BioPharma has made 1 acquisition, including Mereo BioPharma.
Who are Mereo BioPharma's investors?
Mereo BioPharma has 12 investors. Key investors include Astrazeneca, Citadel, Orbimed, Invesco Perpetual, and Woodford Investment Management.
What is Mereo BioPharma's ticker symbol?
The ticker symbol of Mereo BioPharma is MREO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.